Rachael L Morton1, Nicole Lioufas2,3, Kathryn Dansie4,5, Suetonia C Palmer6, Matthew D Jose4,7, Rajesh Raj8, Andrew Salmon9, Matthew Sypek4,10, Allison Tong11, Marie Ludlow12, Neil Boudville13, Stephen McDonald4,5,14. 1. NHMRC Clinical Trials Centre, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. 2. Department of Nephrology, Western Health, Sunshine Hospital, Melbourne, Victoria, Australia. 3. Western Clinical School, School of Medicine, The University of Melbourne, Melbourne, Victoria, Australia. 4. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), Adelaide, South Australia, Australia. 5. University of Adelaide, Adelaide, South Australia, Australia. 6. University of Otago Christchurch, Christchurch, New Zealand. 7. School of Medicine, University of Tasmania, Hobart, Tasmania, Australia. 8. Launceston General Hospital, Launceston, Tasmania, Australia. 9. Renal Service, Waitemata District Health Board, Auckland, New Zealand. 10. Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. 11. Sydney School of Public Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. 12. Kidney Health Australia, Adelaide, Australia. 13. Medical School, University of Western Australia, Perth, Australia. 14. Central and Northern Renal Transplant Service, Royal Adelaide Hospital, Adelaide, Australia.
Abstract
AIM: Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) are increasingly used in research to quantify how patients feel and function, and their experiences of care, however, knowledge of their utilization in routine nephrology is limited. METHODS: The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) PROMs working group conducted a prospective cross-sectional survey of PROMs/PREMs use among renal 'parent hospitals'. One survey per hospital was completed (August-November 2017). Descriptive statistics reported type and frequency of measures used and purpose of use. RESULTS: Survey response rate was 100%. Fifty-five of 79 hospitals (70%) used at least one PROMs or PREMs for specific patient groups. PROMs were more likely to be collected from patients receiving comprehensive conservative care (45% of hospitals) than dialysis patients (32%, 31% and 28% of hospitals for home haemodialysis, peritoneal dialysis and facility dialysis, respectively). Few renal transplanting hospitals (3%) collected PROMs. The Integrated Palliative Outcome Scale-Renal (IPOS-Renal) (40% of units), and the Euro-Qol (EQ-5D-5 L) (25%), were most frequently used. The main reason for collecting PROMs was to inform clinical care (58%), and for PREMs was to fulfil private dialysis/hospital provider requirements (25%). The most commonly reported reason for not using PROMs in 24 hospitals was insufficient staff resources (79%). Sixty-two hospitals (78%) expressed interest in participating in a registry-based PROMs trial. CONCLUSION: Many renal hospitals in Australia and New Zealand collect PROMs and/or PREMs as part of clinical care with use varying by treatment modality. Resources are a key barrier to PROMs use.
AIM: Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) are increasingly used in research to quantify how patients feel and function, and their experiences of care, however, knowledge of their utilization in routine nephrology is limited. METHODS: The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) PROMs working group conducted a prospective cross-sectional survey of PROMs/PREMs use among renal 'parent hospitals'. One survey per hospital was completed (August-November 2017). Descriptive statistics reported type and frequency of measures used and purpose of use. RESULTS: Survey response rate was 100%. Fifty-five of 79 hospitals (70%) used at least one PROMs or PREMs for specific patient groups. PROMs were more likely to be collected from patients receiving comprehensive conservative care (45% of hospitals) than dialysis patients (32%, 31% and 28% of hospitals for home haemodialysis, peritoneal dialysis and facility dialysis, respectively). Few renal transplanting hospitals (3%) collected PROMs. The Integrated Palliative Outcome Scale-Renal (IPOS-Renal) (40% of units), and the Euro-Qol (EQ-5D-5 L) (25%), were most frequently used. The main reason for collecting PROMs was to inform clinical care (58%), and for PREMs was to fulfil private dialysis/hospital provider requirements (25%). The most commonly reported reason for not using PROMs in 24 hospitals was insufficient staff resources (79%). Sixty-two hospitals (78%) expressed interest in participating in a registry-based PROMs trial. CONCLUSION: Many renal hospitals in Australia and New Zealand collect PROMs and/or PREMs as part of clinical care with use varying by treatment modality. Resources are a key barrier to PROMs use.
Authors: Lavern Greenham; Paul N Bennett; Kathryn Dansie; Andrea K Viecelli; Shilpanjali Jesudason; Rebecca Mister; Brendan Smyth; Portia Westall; Samuel Herzog; Chris Brown; William Handke; Suetonia C Palmer; Fergus J Caskey; Cecile Couchoud; John Simes; Stephen P McDonald; Rachael L Morton Journal: Trials Date: 2022-05-19 Impact factor: 2.728
Authors: Margaret H Sandham; Emma Hedgecock; Mevhibe Hocaoglu; Celia Palmer; Rebecca J Jarden; Ajit Narayanan; Richard J Siegert Journal: Int J Environ Res Public Health Date: 2022-06-24 Impact factor: 4.614
Authors: Yiman Wang; Jaapjan D Snoep; Marc H Hemmelder; Koen E A van der Bogt; Willem Jan W Bos; Paul J M van der Boog; Friedo W Dekker; Aiko P J de Vries; Yvette Meuleman Journal: Clin Kidney J Date: 2021-01-20
Authors: Patricia Bonilla-Sierra; Ana Magdalena Vargas-Martínez; Fatima Leon-Larios; Joselin Valeria Arciniega Carrión; Tatiana Cecibel Jiménez Alverca; María de Las Mercedes Lomas-Campos; José Rafael González-López Journal: Int J Environ Res Public Health Date: 2021-05-16 Impact factor: 3.390
Authors: Emily Duncanson; Paul N Bennett; Andrea Viecelli; Kathryn Dansie; William Handke; Allison Tong; Suetonia Palmer; Shilpanjali Jesudason; Stephen P McDonald; Rachael L Morton Journal: BMJ Open Date: 2020-11-06 Impact factor: 2.692